59.50 +0.97 (1.66%)
After hours: 5:47PM EDT
|Bid||58.75 x 100|
|Ask||59.75 x 100|
|Day's Range||58.16 - 59.29|
|52 Week Range||37.35 - 63.77|
|PE Ratio (TTM)||-23.20|
|Earnings Date||Oct 31, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||74.42|
SAN DIEGO, Oct. 23, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that valbenazine, a novel selective vesicular monoamine transporter 2 (VMAT2), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients with Tourette syndrome. Tourette syndrome is a neurological disorder that becomes evident in early childhood or adolescence and is characterized by motor and vocal tics. Valbenazine is marketed in the United States as INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia.
In the first half of 2017, Neurocine Biosciences (NBIX) generated revenues of $6.3 billion and reported expenses on the cost of product sales of $61.0 million.
Neurocrine Biosciences Inc. shares rose 3% in premarket trade Thursday after the company said the Food and Drug Administration has approved a higher, 80 mg dose of its tardive dyskinesia drug. The 80 mg ...
SAN DIEGO, Oct. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved an 80 mg INGREZZA® (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, which was approved by the FDA April 11, 2017, is the first FDA-approved product indicated for the treatment of adults with TD. "INGREZZA continues to be the TD treatment of choice," said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences.
NEW YORK, NY / ACCESSWIRE / September 22, 2017 / Shares of Neurocrine saw a pop on Thursday after a Baird analyst reiterated an "outperform" rating on the stock. Shares of BioCryst also saw gains ...
Neurocrine Biosciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
SAN DIEGO, Sept. 15, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NBIX) announced today upcoming poster presentations at the 2017 Annual Psych Congress featuring data from the RE-KINECT study outlining the real-world presence and impact of tardive dyskinesia (TD) on the lives of both patients and caregivers. "This year's Psych Congress serves as an excellent opportunity to dive deeper into the patient impact of TD, including demographics and healthcare utilization. The RE-KINECT study provides valuable insight into the complexities and needs of these patients and how INGREZZA can address the movements that may disrupt patient lives," said Chris O'Brien, M.D., Chief Medical Officer of Neurocrine.
Live Audio Webcast Will be on September 11, 2017 SAN DIEGO , Sept. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, ...
- In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual pelvic pain and painful ...
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a "hold."
Live Audio Webcast Will be on September 6, 2017 SAN DIEGO , Aug. 30, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman , CEO of Neurocrine Biosciences, ...
Neurocrine Biosciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82.
NEW YORK, NY / ACCESSWIRE / August 25, 2017 / U.S. markets closed in the red Thursday as investors await comments on monetary policy from the annual meeting of central bankers in Jackson Hole, Wyoming. ...